Table of Contents 2
List of Tables 4
List of Figures 4
4SC AG Spshot 5
4SC AG Overview 5
Key Information 5
Key Facts 5
4SC AG - Research and Development Overview 6
Key Therapeutic Areas 6
4SC AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combition Treatment Modalities 12
4SC AG - Pipeline Products Glance 13
4SC AG - Clinical Stage Pipeline Products 13
Phase II Products/Combition Treatment Modalities 13
Phase I Products/Combition Treatment Modalities 14
4SC AG - Early Stage Pipeline Products 15
Preclinical Products/Combition Treatment Modalities 15
Discovery Products/Combition Treatment Modalities 16
4SC AG - Drug Profiles 17
resminostat 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
vidofludimus 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
4SC-202 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
4SC-205 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule for Malaria 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules for Neurological Disorders 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit Bromodomain for Cancer 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
4SC AG - Pipeline Alysis 34
4SC AG - Pipeline Products by Target 34
4SC AG - Pipeline Products by Route of Administration 35
4SC AG - Pipeline Products by Molecule Type 36
4SC AG - Pipeline Products by Mechanism of Action 37
4SC AG - Recent Pipeline Updates 38
4SC AG - Dormant Projects 45
4SC AG - Discontinued Pipeline Products 46
Discontinued Pipeline Product Profiles 46
4SC-203 46
4SC-207 46
resminostat 46
4SC AG - Company Statement 47
4SC AG - Locations And Subsidiaries 49
Head Office 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51